Literature DB >> 3024871

A study of corticotroph adenomas in Cushing's disease: no evidence of intermediate lobe origin.

A M McNicol, G M Teasdale, G H Beastall.   

Abstract

There is little evidence for a separate functional or anatomical intermediate lobe in the adult human pituitary gland. Nevertheless, Lamberts et al. (1982) proposed that a subgroup of corticotroph adenomas in Cushing's disease arise in that lobe and can be identified by the presence of argyrophil (? neural) fibres, and that these tumours are more often associated with corticotroph hyperplasia and hyperprolactinaemia than those arising in the anterior lobe. We have examined a series of corticotroph adenomas from patients with Cushing's disease for evidence of argyrophil fibres, and have correlated this with tumour site, corticotroph distribution in the para-adenomatous gland, serum PRL levels and PRL immunoreactive cells in the tumour. Argyrophil fibres were identified not only in tumours adjacent to the posterior lobe, but also in tumours situated deep in the anterior lobe. There was no correlation between the presence of fibres or the site of the tumour and corticotroph hyperplasia. Whilst the two patients with the highest serum PRL levels did have argyrophil fibres they also had a subpopulation of PRL immunoreactive cells in the tumour. On the basis of these results, we propose that the 'intermediate lobe' hypothesis as outlined above should not be accepted.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3024871     DOI: 10.1111/j.1365-2265.1986.tb01668.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  Diversity of ACTH-immunoreactive cells in the human adenohypophysis: an immunohistochemical study with special reference to cluster formation and follicular cell association.

Authors:  Michiko Yamashita; Toshiaki Sano; Zhi Rong Qian; Kalman Kovacs; Eva Horvath
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.

Authors:  R Pivonello; A Faggiano; F Di Salle; M Filippella; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

4.  An unusual presentation of pediatric Cushing disease: recurrent corticotropinoma of the posterior pituitary lobe.

Authors:  Monalisa F Azevedo; Paraskevi Xekouki; Meg F Keil; Eileen Lange; Nicholas Patronas; Constantine A Stratakis
Journal:  J Pediatr Endocrinol Metab       Date:  2010-06       Impact factor: 1.634

5.  Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines.

Authors:  W E Farrell; A J Clark; M F Stewart; S R Crosby; A White
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine?

Authors:  G Francia; M V Davì; E Montresor; C Colato; M Ferdeghini; V Lo Cascio
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 5.467

Review 7.  Role of "old" pharmacological agents in the treatment of Cushing's syndrome.

Authors:  A G Ambrogio; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2016-04-16       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.